Skip to main content
. Author manuscript; available in PMC: 2022 Nov 1.
Published in final edited form as: Neuropharmacology. 2022 Aug 22;218:109233. doi: 10.1016/j.neuropharm.2022.109233

Fig. 2. ELB00824 attenuated cold hyperalgesia and mechanical allodynia produced by oxaliplatin.

Fig. 2.

(A-D) In the female (A, B) and male (C, D) mouse model of acute OIPN, at the end of oxaliplatin (Oxa) treatment period at day 6 post drug injection (PDI), the prevention effect of ELB00824 (ELB) on cold hyperalgesia (A, C) and mechanical allodynia (B, D) was assessed (n = 8/group). (E-H) In the female mouse model of chronic OIPN, at the end of oxaliplatin treatment period (E, F at 4 week PDI), and follow-up period (G, H at 8 week PDI), the prevention effect of ELB on cold hyperalgesia (E, G) and mechanical allodynia (F, H) was assessed (n = 10/group). (I-J) In the female mouse model of chronic OIPN, at the end of oxaliplatin treatment period, the treatment effect of ELB on cold hyperalgesia (I) and mechanical allodynia (J) was assessed (n = 8/group). ELB 30: ELB00824 30 mg/kg. ELB 10: ELB00824 10 mg/kg. ELB 3: ELB00824 3 mg/kg. Veh: Vehicle. In figures A-H, the box-and-whiskers plots show minimum, maximum, median and 25th and 75th percentiles; while in figure I-J, symbols at mean and error bars at standard deviation (SD) are superimposed with connecting line. Inter-group comparison was done using one-way ANOVA, followed by Dunn’s test. *: p ≤ 0.05; **: p ≤ 0.01; ***: p ≤ 0.001 vs Veh Control or Veh group. #: p ≤ 0.05; ##: p ≤ 0.01; ###: p ≤ 0.001; ####: p ≤ 0.0001 vs Oxa Control group. Dashed line is the mean value of Oxa control group at the end of oxaliplatin treatment period in the chronic OIPN model.